Notch 3 Protein, not its Gene Polymorphism, is Associated with the Chemotherapy Response and Prognosis of Advanced NSCLC Patients

Background.Osteopontin (OPN) is associated with prognosis of patients with non-small-cell lung cancer (NSCLC). However, little is known about the association between OPN gene polymorphism and the chemotherapy response in NSCLC patients.Methods.A total of 497 patients with inoperable advanced stage of NSCLC (stages III B and IV NSCLC) were enrolled. All patients had received platinum-based chemotherapy. OPN gene polymorphisms at 156 GG/G, 443 C/T, and −66T/G were determined.Results.The genotypes and allele frequency of −443C>T were significantly different between the responders and nonresponders. Responders had a markedly higher frequency of −443TT genotype than responders (40.71% versus 19.09%,P<0.001). With CC as reference, the TT genotype carriers had a higher chance to be well responders (adjustedOR=4.43, 95% CI: 2.60–7.53, adjustedP<0.001). The median overall survival time for patients with −443CC, −443CT, and −443TT genotype carriers was significantly different. Multivariate Cox proportional hazards regression models showed that OPN −443C>T gene polymorphisms were closely correlated to poor NSCLC prognosis.Conclusion.OPN −443C>T gene polymorphism may be used as a molecular marker to predict the treatment response to chemotherapy in advanced NSCLC patients.

Download Full-text

Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients

Cancer Letters ◽

10.1016/j.canlet.2016.04.029 ◽

2016 ◽

Vol 377 (1) ◽

pp. 65-73 ◽

Cited By ~ 12

Author(s):

Ji-Ye Yin ◽

Xi Li ◽

Xiang-Ping Li ◽

Ling Xiao ◽

Wei Zheng ◽

...

Keyword(s):

Prediction Models ◽

Advanced Nsclc ◽

Chemotherapy Response ◽

Platinum Based Chemotherapy ◽

Nsclc Patients

Download Full-text

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

BioMed Research International ◽

10.1155/2014/801640 ◽

2014 ◽

Vol 2014 ◽

pp. 1-8 ◽

Cited By ~ 7

Author(s):

Sun Xian ◽

Lang Jilu ◽

Tian Zhennan ◽

Zhou Yang ◽

Hu Yang ◽

...

Keyword(s):

Genetic Variants ◽

Advanced Nsclc ◽

Nonsmall Cell Lung Cancer ◽

Tissue Expression ◽

Chemotherapy Response ◽

Potential Predictor ◽

Bone Morphogenic Proteins ◽

Platinum Based Chemotherapy ◽

Nsclc Patients

To explore the role of genetic polymorphisms of bone morphogenic proteins 4 (BMP-4) in the response to platinum-based chemotherapy and the clinical outcome in patients with advanced nonsmall cell lung cancer (NSCLC), 938 patients with stage III (A+B) or IV NSCLC were enrolled in this study. We found that the variant genotypes of 6007C > T polymorphisms significantly associated with the chemotherapy response. The 6007CC genotype carriers had a higher chance to be responder to chemotherapy (adjusted odd ratio = 2.77; 95% CI: 1.83–4.18; adjusted < 0.001). The 6007C > T polymorphisms and BMP-4 expression also affect the prognosis of NSCLC. Patients with high BMP-4 expression had a significantly higher chance to be resistant to chemotherapy than those with low BMP-4 expression (OR = 2.81; 95% CI: 1.23–6.44;P=0.01). The hazard ratio (HR) for 6007TT was 2.37 times higher than 6007CC (P=0.003). In summary, the 6007C > T polymorphism of BMP-4 gene and BMP-4 tissue expression may be used as potential predictor for the chemotherapy response and prognosis of advanced NSCLC.

Download Full-text

WITHDRAWN: Tumor SOCS3 protein expression, instead of SOCS3 promoter methylation status, predicts chemotherapy response and prognosis in advanced NSCLC patients

Oncotarget ◽

10.18632/oncotarget.23108 ◽

2017 ◽

Vol 0 (0) ◽

Author(s):

Jinhong Wang ◽

Dong Kang ◽

Yu Yao ◽

Anna Shen ◽

Deguang Yang ◽

...

Keyword(s):

Protein Expression ◽

Promoter Methylation ◽

Advanced Nsclc ◽

Methylation Status ◽

Chemotherapy Response ◽

Promoter Methylation Status ◽

Nsclc Patients ◽

Socs3 Protein

Download Full-text

Correlation between MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced NSCLC: A meta-analysis

Pteridines ◽

10.1515/pteridines-2020-0026 ◽

2021 ◽

Vol 32 (1) ◽

pp. 23-32

Author(s):

Feng Han ◽

Wengui Xu

Keyword(s):

Clinical Studies ◽

Advanced Nsclc ◽

Meta Analysis ◽

Objective Response ◽

Dominant Gene ◽

Chemotherapy Response ◽

China National Knowledge Infrastructure ◽

Knowledge Infrastructure ◽

Regression Test ◽

Nsclc Patients

Abstract Objective The aim of this study was to investigate the correlation between MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced non-small-cell lung cancer (NSCLC) by pooling the open published relevant studies. Methods Clinical studies associated with MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced NSCLC were systematically searched in databases of Pubmed, Embase, Cochrance Library, China national knowledge infrastructure (CNKI) and Wanfang. The correlation was expressed by odds ratio (OR) and corresponding 95% confidence interval (95% CI). The publication bias of the included studies was evaluated through Begg’s funnel plot and Egger’s line regression test. Results Ten prospective clinical studies relevant to MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in NSCLC were included in the present meta-analysis. The pooled results indicated that the partial response in NSCLC patients with TT or CT genotype was inferior to CC genotype in a dominant gene model (TT + CT vs CC) (OR = 0.16, 95% CI: 0.06–0.41, P = 0.001). NSCLC cases with T genotype were inferior to C genotype in the objective response rate treated with pemetrexed-based chemotherapy for dominant (OR = 0.28, 95% CI: 0.18–0.45, P = 0.001), recessive (OR = 0.43, 95% CI: 0.19–0.94, P = 0.03) and homozygous models (OR = 0.30, 95% CI: 0.13–0.67, P = 0.003). However, there was no statistical difference in disease control rate, progressive disease between different genotypes of different gene models (P all > 0.05). Conclusion The pemetrexed-based chemotherapy response was decreased in NSCLC cases with T genotype, which can be applied as a potential pemetrexed-based chemotherapy response marker.

Download Full-text